But in recent years, several clubs have brought boffins on board in the hopes of boosting their chances of success. Liverpool has partnered with Google's AI firm DeepMind to advise coaches on corner kicks, while other clubs have hired astrophysicists to analyse data and are even using missile-tracking technology to plot the move of every player. So, can science really tell us how to bend it like Beckham? MailOnline spoke to experts to uncover the formula for the winning football match ahead of Manchester United's match against Liverpool this Sunday. Can science really tell us how to bend it like Beckham? MailOnline spoke to experts to uncover the formula for the winning football match ahead of Manchester United's match against Liverpool this Sunday Taking a penalty is surely the most nerve-wracking experience for any player – a single moment that can decide the result of an entire tournament.

Alzheimer's patients gradually lose their ability to think, behave, and interact with others. Medical history, laboratory tests, daily activities, and personality changes can all be used to diagnose the disorder. A series of time-consuming and expensive tests are used to diagnose the illness. The most effective way to identify Alzheimer's disease is using a Random-forest classifier in this study, along with various other Machine Learning techniques. The main goal of this study is to fine-tune the classifier to detect illness with fewer tests while maintaining a reasonable disease discovery accuracy. We successfully identified the condition in almost 94% of cases using four of the thirty frequently utilized indicators.

Ulster University engaged with Dell Technologies and global partner NVIDIA to implement a high-speed computing power platform required to train AI models on ever-larger datasets. This is the first Dell Tech AI Ready Solution deployed in the EMEA region and represents a significant investment from the University. By putting in place next generation servers, high performance computing (HPC) software and other supporting infrastructure, researchers at Ulster University will be able to apply AI to predict illnesses before they emerge and put in place preventative measures that help to treat patients from the comfort of their own homes. The data scientist team at Ulster University's School of Computing are planning to use the transformative power of AI in detecting early signs of diabetic foot disease, enabling suffers to effectively manage the condition without hospitalisation. There are currently over 81,000 adults and 1,000 young people with diabetes in Northern Ireland and over 400 million adults globally.

Researchers at Ulster University have published the results of their work on developing the first biological neural network model equipped with self-awareness, a form of metacognition. This breakthrough research could have important implications in providing insights into brain disorders related to distorted self-awareness, or the development of self-aware artificial intelligence (AI) machines. The Intelligent Systems Research Centre (ISRC) at Ulster University's Magee campus in Derry is the site of this pioneering research, which was recently published in the prestigious journal, Nature Communications. For years, researchers at ISRC have been working on developing and applying biologically inspired algorithms that go beyond standard AI algorithms, leveraging the solutions nature provided to solving complex problems in computing and AI. This includes utilising knowledge in brain sciences towards the development of superior and efficient computer algorithms or machines.

A pioneering new clinical trial on a drug that could potentially help millions of men with prostate cancer, is under way in Derry. Tumour samples from men being treated locally are being collated to test the drug's effectiveness at the Clinical Transitional Research and Innovation Centre (C-TRIC), labs on the Altnagelvin Hospital site. The new trials are the result of a partnership with American pharmaceutical company Lantern Pharma and the PRAISE (prostate cancer artificial intelligence study using ex vivo models) trial is using artificial intelligence to test a cancer drug called LP-184 to predict which types of tumours are sensitive to it. The company said the groundbreaking work, which is partially funded by Invest NI, does not involve human or animals trials due to the use of AI. The new project will help guide future cancer research and clinical trials and early indications suggest there could also be benefits for research into the treatment of ovarian and liver cancer.

A pioneering new clinical trial on a drug that could potentially help millions of men with prostate cancer, is under way in Derry. Tumour samples from men being treated locally are being collated to test the drug's effectiveness at the Clinical Transitional Research and Innovation Centre (C-TRIC), labs on the Altnagelvin Hospital site. The new trials are the result of a partnership with American pharmaceutical company Lantern Pharma and the PRAISE (prostate cancer artificial intelligence study using ex vivo models) trial is using artificial intelligence to test a cancer drug called LP-184 to predict which types of tumours are sensitive to it. The company said the groundbreaking work, which is partially funded by Invest NI, does not involve human or animals trials due to the use of AI. The new project will help guide future cancer research and clinical trials and early indications suggest there could also be benefits for research into the treatment of ovarian and liver cancer.